Advanced Melanoma Market Report 2026

Advanced Melanoma Market Overview

• Advanced Melanoma market size has reached to $4.12 billion in 2025 • Expected to grow to $6.37 billion in 2030 at a compound annual growth rate (CAGR) of 9.1% • Growth Driver: Rising Sunburn Incidents Fuel Growth Of The Market • Market Trend: Innovative Personalized Vaccines Driving Advanced Melanoma Treatment Advancements • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Advanced Melanoma Market?

Advanced melanoma refers to melanoma skin cancer that has spread beyond the original site to other parts of the body. It includes stage III (spread to nearby lymph nodes) and stage IV (metastasized to distant organs l), which is more challenging to treat and often requires a combination of therapies, such as immunotherapy, targeted therapy, chemotherapy, or radiation. The main therapeutics of advanced melanoma are chemotherapy, biological therapy, targeted therapy, and immune therapy. Chemotherapy for advanced melanoma refers to the use of drugs to kill or slow the growth of rapidly dividing cancer cells. The various distribution channels include hospital pharmacy, online pharmacy, and retail pharmacy, and several end-users including hospitals, cancer research centers, academic institutes, diagnostic centers, ambulatory surgical centers, and others.

What Is The Advanced Melanoma Market Growth Forecast?

The advanced melanoma market size is expected to see strong growth in the next few years. It will grow to $6.37 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to advancement in immune checkpoint inhibitors, increasing use of targeted therapies like BRAF and MEK inhibitors, expansion of personalized medicine approaches, growing investment in melanoma research, integration of digital health and patient monitoring solutions. Major trends in the forecast period include rising adoption of immunotherapy and targeted therapies, increasing use of biomarker-based treatment selection, expansion of hospital and oncology center capabilities, growing focus on early detection and diagnostic tools, increasing clinical trials and research on advanced melanoma.

Global Advanced Melanoma Market Segmentation

1) By Therapeutics: Chemotherapy, Biological Therapy, Targeted Therapy, Immune Therapy 2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy 3) By End-User: Hospitals, Cancer Research Centres, Academic Institutes, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users Subsegments: 1) By Chemotherapy: Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors, Other Chemotherapy Drugs 2) By Biological Therapy: Monoclonal Antibodies, Interferons, Interleukins 3) By Targeted Therapy: BRAF Inhibitors, MEK Inhibitors, KIT Inhibitors, Other Targeted Therapies 4) By Immune Therapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Oncolytic Virus Therapy, Adoptive Cell Transfer

What Is The Driver Of The Advanced Melanoma Market?

The increasing number of cases of severe sunburns is expected to propel the growth of the advanced melanoma market going forward. Severe sunburns are intense skin burns caused by excessive exposure to ultraviolet (UV) radiation, resulting in redness, pain, swelling, and sometimes blistering. The increasing number of severe sunburn cases is due to prolonged exposure to ultraviolet (UV) radiation, lack of proper sun protection measures, increased outdoor activities during peak UV hours, and rising temperatures due to climate change. Severe sunburns, especially those occurring repeatedly or at a young age, cause DNA damage in skin cells, which can lead to genetic mutations that trigger melanoma. For instance, in May 2024, according to Melanoma Focus, a UK-based charity dedicated to supporting the melanoma community, in 2022-23, there were 201 hospital admissions due to sunburn, including 89 children and 25 babies under one-year-old. Further, 66% of UK adults aged 16-65 remembered getting sunburned as children, and 65% experienced severe sunburn with blisters at least once. This number rose to 77% for those with light, pale, or white skin. Therefore, the increasing number of cases of severe sunburns is driving the growth of the advanced melanoma industry.

Key Players In The Global Advanced Melanoma Market

Major companies operating in the advanced melanoma market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca AG, Novartis AG, Amgen Inc., BioNTech SE, Regeneron Pharmaceuticals, Genentech Inc., Exelixis Inc., Dynavax Technologies, Replimune Group, Immunocore Holdings plc, Xencor Inc., Agenus Inc., Nektar Therapeutics, Iovance Biotherapeutics, Adaptimmune Therapeutics, Immutep Ltd., Lytix Biopharma

Global Advanced Melanoma Market Trends and Insights

Major companies operating in the advanced melanoma market are focusing on developing innovative products, such as personalized vaccines, to improve treatment efficacy, overcome resistance mechanisms, and provide personalized treatment options that can lead to better patient outcomes and prolonged survival. A personalized vaccine for advanced melanoma is a type of cancer treatment designed specifically for an individual patient based on the unique genetic mutations in their tumor. For instance, in April 2023, Merck & Co. Inc., a US-based pharmaceutical company, and Moderna Inc., a US-based biotechnology company, received Priority Medicines (PRIME) scheme designation from the European Medicines Agency (EMA) for their investigational personalized mRNA cancer vaccine, mRNA-4157/V940, when used in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection. The personalized cancer vaccine mRNA-4157/V940 comprises a single synthetic mRNA coding for up to 34 neoantigens and is designed and produced based on the unique mutational signature of the patient’s tumor.

What Are Latest Mergers And Acquisitions In The Advanced Melanoma Market?

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. With this acquisition, Pfizer’s oncology pipeline has doubled in size with 60 programs spanning multiple modalities and will leverage its leading protein engineering and medicinal chemistry capabilities to advance Seagen’s antibody-drug conjugate (ADC) technology, unlocking potential novel combinations and next-generation biologics. Seagen Inc. is a US-based biotechnology company actively researching and developing treatments for advanced melanoma, focusing on using its antibody-drug conjugate (ADC) technology.

Regional Outlook

North America was the largest region in the advanced melanoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Advanced Melanoma Market?

The advanced melanoma market consists of revenues earned by entities by providing services such as diagnosis and staging, surgical excision, immunotherapy administration, targeted therapy management, palliative care and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced melanoma market also includes sales of pembrolizumab, vemurafenib, trametinib, and personalized cancer vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Advanced Melanoma Market Report 2026?

The advanced melanoma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the advanced melanoma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.